CML is now treated with third-generation TKIs (ponatinib), which are more effective in inhibiting BCR-ABL kinase, and second-generation TKIs like nilotinib, dasatinib, and bosutinib. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.